The existence of blood–brain barrier (BBB) hampers the effective treatment of central
nervous system (CNS) diseases. Almost all macromolecular drugs and more than 98% of …

A major limiting factor for the treatment of central nervous system (CNS) related disorders is
the inability for drug substances to cross the blood-brain barrier. Some medications may …

The aim of the present work was to investigate the efficacy of temozolomide nanostructured
lipid carriers (TMZ-NLCs) to enhance brain targeting via nasal route administration. The …

Over the past few years, nasal drug delivery has attracted more and more attentions, and
been recognized as the most promising alternative route for the systemic medication of …

Protection of substantia nigra (SN) dopaminergic (DA) neurons by neurotrophic factors
(NTFs) is one of the promising strategies in Parkinson's disease (PD) therapy. A major …

The present study was carried out to investigate the intranasal delivery of astaxanthin as
solid lipid nanoparticles with the intention of improving brain targeting of astaxanthin for …

During the development of intranasal drug delivery systems for local/systemic effect or brain
targeting, it is necessary to assess its cytotoxicity and drug transport through nasal …

Present investigation deals with design, development and evaluation of chitosan-based
spray-dried nasal mucoadhesive microspheres loaded with diltiazem hydrochloride (DTZ …

Introduction: The brain–blood ratio is an important model correlating the brain-targeting
ability of neurotherapeutics with the CNS pharmacokinetics, which need to be presented …

Metastasis to the central nervous system remains difficult to treat, and such patients are
faced with a dismal prognosis. The blood-brain barrier (BBB), despite being partially …